Evaluation of Clinical and Immunological Markers for Predicting Virological Failure in a HIV/AIDS Treatment Cohort in Busia, Kenya
Open Access
- 21 November 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11) , e49834
Abstract
In resource-limited settings where viral load (VL) monitoring is scarce or unavailable, clinicians must use immunological and clinical criteria to define HIV virological treatment failure. This study examined the performance of World Health Organization (WHO) clinical and immunological failure criteria in predicting virological failure in HIV patients receiving antiretroviral therapy (ART). In a HIV/AIDS program in Busia District Hospital, Kenya, a retrospective, cross-sectional cohort analysis was performed in April 2008 for all adult patients (>18 years old) on ART for ≥12 months, treatment-naive at ART start, attending the clinic at least once in last 6 months, and who had given informed consent. Treatment failure was assessed per WHO clinical (disease stage 3 or 4) and immunological (CD4 cell count) criteria, and compared with virological failure (VL >5,000 copies/mL). Of 926 patients, 123 (13.3%) had clinically defined treatment failure, 53 (5.7%) immunologically defined failure, and 55 (6.0%) virological failure. Sensitivity, specificity, positive predictive value, and negative predictive value of both clinical and immunological criteria (combined) in predicting virological failure were 36.4%, 83.5%, 12.3%, and 95.4%, respectively. In this analysis, clinical and immunological criteria were found to perform relatively poorly in predicting virological failure of ART. VL monitoring and new algorithms for assessing clinical or immunological treatment failure, as well as improved adherence strategies, are required in ART programs in resource-limited settings.Keywords
This publication has 14 references indexed in Scilit:
- Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trialBMJ, 2011
- Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoringAIDS, 2009
- Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in UgandaAIDS, 2009
- Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switchingAIDS, 2008
- Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South AfricaAIDS, 2008
- Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic ReviewPLOS Medicine, 2007
- HIV Viral Load Monitoring in Resource‐Limited Regions: Optional or Necessary?Clinical Infectious Diseases, 2007
- Can Routine Clinical Markers Be Used Longitudinally to Monitor Antiretroviral Therapy Success in Resource‐Limited Settings?Clinical Infectious Diseases, 2007
- Performance of Immunologic Responses in Predicting Viral Load SuppressionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Highly active antiretroviral therapy in resource-poor settingsAIDS, 2003